{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T12:40:01Z","timestamp":1747140001402,"version":"3.40.5"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T00:00:00Z","timestamp":1743897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["259373024","441891347","SFB-1479"],"award-info":[{"award-number":["259373024","441891347","SFB-1479"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["EXC-2189","390939984"],"award-info":[{"award-number":["EXC-2189","390939984"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101094168"],"award-info":[{"award-number":["101094168"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.coph.2025.102525","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T10:48:39Z","timestamp":1743936519000},"page":"102525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Strategies to enhance anti-leukaemia immunotherapy"],"prefix":"10.1016","volume":"82","author":[{"given":"Memnon","family":"Lysandrou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2025.102525_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41568-021-00355-z","article-title":"Leukaemia: a model metastatic disease","volume":"21","author":"Whiteley","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.coph.2025.102525_bib2","first-page":"2813","article-title":"How I treat AML incorporating the updated classifications and guidelines","volume":"141","author":"El Chaer","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2021012411","article-title":"How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy","volume":"141","author":"Biederst\u00e4dt","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib4","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102525_bib5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102525_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102525_bib7","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102525_bib8","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102525_bib9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cell.2015.05.047","article-title":"Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis","volume":"162","author":"Levine","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102525_bib10","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102525_bib11","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","article-title":"First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia","volume":"15","author":"Jin","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.coph.2025.102525_bib13","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_sref14","first-page":"1","article-title":"Cytokine-mediated CAR T therapy resistance in AML","author":"Bhagwat","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102525_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MOH.0000000000000703","article-title":"Chimeric antigen receptor T-cell therapy in acute myeloid leukemia","volume":"29","author":"Koedam","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.coph.2025.102525_bib16","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"Gill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib17","first-page":"1","article-title":"Linking CRISPR\u2013Cas9 double-strand break profiles to gene editing precision with BreakTag","author":"Longo","year":"2024","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coph.2025.102525_bib18","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102525_bib19","doi-asserted-by":"crossref","first-page":"11978","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.coph.2025.102525_sref20","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102525_sref21","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_sref22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-024-07456-3","article-title":"Selective haematological cancer eradication with preserved haematopoiesis","volume":"630","author":"Garaud\u00e9","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102525_bib23","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231235","article-title":"Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy","volume":"220","author":"Marone","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.coph.2025.102525_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abh1962","article-title":"Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence","volume":"13","author":"Katsarou","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_sref25","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102525_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coph.2025.102525_bib27","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","article-title":"Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function","volume":"175","author":"Shifrut","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102525_bib28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","article-title":"A genome-scale screen for synthetic drivers of T cell proliferation","volume":"603","author":"Legut","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102525_sref29","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","article-title":"Modular pooled discovery of synthetic knockin sequences to program durable cell therapies","volume":"186","author":"Blaeschke","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.coph.2025.102525_bib30","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccell.2022.06.001","article-title":"Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence","volume":"40","author":"Belk","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102525_bib31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","article-title":"BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells","volume":"22","author":"Seo","year":"2021","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2025.102525_bib32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.coph.2025.102525_bib33","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102525_bib34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","article-title":"Mechanisms of immune escape after allogeneic hematopoietic cell transplantation","volume":"133","author":"Zeiser","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib35","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","article-title":"Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT","volume":"10","author":"Noviello","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102525_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.coph.2025.102525_bib37","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102525_bib38","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood.2021010867","article-title":"Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation","volume":"137","author":"Penter","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coph.2025.102525_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177460","article-title":"Oncogene-induced TIM-3 ligand expression dictates susceptibility to anti\u2013TIM-3 therapy in mice","volume":"134","author":"Talvard-Balland","year":"2024","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coph.2025.102525_bib41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/ni.3410","article-title":"A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet","volume":"17","author":"Xin","year":"2016","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coph.2025.102525_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.coph.2025.102525_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2023-180876","article-title":"TIM-3 inhibitor sabatolimab for patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) detected after Allogeneic Stem Cell Transplantation (AlloSCT): preliminary findings from the phase Ib\/II stimulus-AML2 study","volume":"142","author":"Zeiser","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib44","doi-asserted-by":"crossref","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_bib45","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.3324\/haematol.2020.259457","article-title":"Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model","volume":"106","author":"Stroopinsky","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.coph.2025.102525_bib46","doi-asserted-by":"crossref","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","article-title":"CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function","volume":"14","author":"Ruggiero","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_bib47","doi-asserted-by":"crossref","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","article-title":"Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency","volume":"14","author":"Lahman","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_bib48","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb8969","article-title":"Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans","volume":"12","author":"Uhl","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_bib49","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2025.102525_bib50","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1182\/blood.2022017795","article-title":"Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib51","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41467-023-35948-9","article-title":"IFN\u03b3 signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells","volume":"14","author":"Mazet","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.coph.2025.102525_bib52","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","article-title":"Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse","volume":"12","author":"Gambacorta","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coph.2025.102525_bib53","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ccell.2022.09.007","article-title":"Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses","volume":"40","author":"Chan","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coph.2025.102525_bib54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood.2022016082","article-title":"Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1\/2 upregulation","volume":"140","author":"Ho","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib55","doi-asserted-by":"crossref","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2025.102525_bib56","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1182\/blood.2021013972","article-title":"Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant","volume":"139","author":"Bednarski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.coph.2025.102525_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm1375","article-title":"Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia","volume":"14","author":"Berrien-Elliott","year":"2022","journal-title":"Sci Transl Med"},{"issue":"Supplement 1","key":"10.1016\/j.coph.2025.102525_bib58","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2023-187058","article-title":"Phase I trial of allogeneic donor gamma delta T cell infusion post-hematopoietic cell transplantation, an interim safety report","volume":"142","author":"Bejanyan","year":"2023","journal-title":"Blood"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489225000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T12:12:28Z","timestamp":1747138348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489225000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":58,"alternative-id":["S1471489225000219"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2025.102525","relation":{},"ISSN":["1471-4892"],"issn-type":[{"type":"print","value":"1471-4892"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies to enhance anti-leukaemia immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2025.102525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102525"}}